Sign Out
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one prior systemic therapy.
This indication is approved under conditional registration which is based on overall response rate (ORR) and duration of response (DOR) [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions]. Continued approval for this indication may be based on the outcome of clinical benefit in a confirmatory trial.
